Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Ovarian Neoplasms

  Free Subscription


17.08.2020

1 BMC Cancer
1 Br J Cancer
1 Cancer
4 Gynecol Oncol
7 Histopathology
1 J Clin Oncol
1 J Natl Cancer Inst


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    BMC Cancer

  1. EL ANSARI FZ, Jouali F, Marchoudi N, Bennani MM, et al
    Screening of BRCA1/2 genes mutations and copy number variations in patients with high risk for hereditary breast and ovarian cancer syndrome (HBOC).
    BMC Cancer. 2020;20:747.
    PubMed         Abstract available


    Br J Cancer

  2. YANG M, Zhang G, Wang Y, He M, et al
    Tumour-associated neutrophils orchestrate intratumoural IL-8-driven immune evasion through Jagged2 activation in ovarian cancer.
    Br J Cancer. 2020 Aug 11. pii: 10.1038/s41416-020-1026.
    PubMed         Abstract available


    Cancer

  3. VYSOTSKAIA V, Kaseniit KE, Bucheit L, Ready K, et al
    Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.
    Cancer. 2020;126:549-558.
    PubMed         Abstract available


    Gynecol Oncol

  4. POTHURI B, O'Cearbhaill R, Eskander R, Armstrong D, et al
    Frontline PARP inhibitor maintenance therapy in ovarian cancer: A Society of Gynecologic Oncology practice statement.
    Gynecol Oncol. 2020 Aug 7. pii: S0090-8258(20)33747.
    PubMed         Abstract available

  5. POWELL CB, Laurent C, Ciaravino G, Garcia C, et al
    Streamlining genetic testing for women with ovarian cancer in a Northern California health care system.
    Gynecol Oncol. 2020 Aug 7. pii: S0090-8258(20)33662.
    PubMed         Abstract available

  6. BEESLEY VL, Webber K, Nagle CM, DeFazio A, et al
    When will I feel normal again? Trajectories and predictors of persistent symptoms and poor wellbeing after primary chemotherapy for ovarian cancer.
    Gynecol Oncol. 2020 Aug 6. pii: S0090-8258(20)33664.
    PubMed         Abstract available

  7. LEE EK, Xiong N, Cheng SC, Barry WT, et al
    Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial.
    Gynecol Oncol. 2020 Aug 5. pii: S0090-8258(20)33663.
    PubMed         Abstract available


    Histopathology

  8. CASEY L, Singh N
    Metastases to the ovary arising from endometrial, cervical and fallopian tube cancer: recent advances.
    Histopathology. 2020;76:37-51.
    PubMed         Abstract available

  9. RABBAN JT, Karnezis AN, Devine WP
    Practical roles for molecular diagnostic testing in ovarian adult granulosa cell tumour, Sertoli-Leydig cell tumour, microcystic stromal tumour and their mimics.
    Histopathology. 2020;76:11-24.
    PubMed         Abstract available

  10. EUSCHER ED, Malpica A
    Gynaecological malignancies and sentinel lymph node mapping: an update.
    Histopathology. 2020;76:139-150.
    PubMed         Abstract available

  11. BERNEY DM, Stoneham S, Arora R, Shamash J, et al
    Ovarian germ cell tumour classification: views from the testis.
    Histopathology. 2020;76:25-36.
    PubMed         Abstract available

  12. VERMIJ L, Smit V, Nout R, Bosse T, et al
    Incorporation of molecular characteristics into endometrial cancer management.
    Histopathology. 2020;76:52-63.
    PubMed         Abstract available

  13. MCCLUGGAGE WG
    Endometriosis-related pathology: a discussion of selected uncommon benign, premalignant and malignant lesions.
    Histopathology. 2020;76:76-92.
    PubMed         Abstract available

  14. WILLIAMS AT, Ganesan R
    Role of the pathologist in assessing response to treatment of ovarian and endometrial cancers.
    Histopathology. 2020;76:93-101.
    PubMed         Abstract available


    J Clin Oncol

  15. TEW WP, Lacchetti C, Ellis A, Maxian K, et al
    PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline.
    J Clin Oncol. 2020 Aug 13:JCO2001924. doi: 10.1200/JCO.20.01924.
    PubMed         Abstract available


    J Natl Cancer Inst

  16. LEE AW, Rosenzweig S, Wiensch A, Ramus SJ, et al
    Expanding our understanding of ovarian cancer risk: the role of incomplete pregnancies.
    J Natl Cancer Inst. 2020 Aug 7. pii: 5885090. doi: 10.1093.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: